CT screening for thrombolysis: Uncertainties remain

Stroke

Volumn 34, Issue 3, 2003, Pages 822-823

  Davis, Stephen M ^a,b   Donnan, Geoffrey A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Computed tomography; Ischemia; Thrombolytic therapy

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; STROKE; SYMPTOMATOLOGY;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; PATIENT SELECTION; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037337419     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000059432.50976.28     Document Type: Short Survey

References (2)

1. Gilligan A, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers BR, Davis SM, Donnan GA, Australian Streptokinase Trial (ASK) Investigators. Baseline blood pressure and not early CT changes predict major hemorrhage after streptokinase in acute ischemic stroke. Stroke. 2002;33:2236-2242.
2. Donnan GA, Davis SM. Neuroimaging: the ischaemic penumbra and selection of patients for acute stroke therapy. Lancet Neurol. In press.